100+ optimized IHC assays
TriStar offers immunohistochemistry (IHC) assays for oncology research on Ventana and Dako platforms, with scoring by our pathologists. Connect your assay to fit-for-purpose cohorts from our translational studies repository. We also offer IHC assay transfer and development for targets outside the library.
THE INTEGRATED SERVICES APPROACH
Samples, services and pathology expertise through one partner
Repository samples
Selected for your study
- Fewer handoffs
- Spend less time coordinating samples and additional work across providers.
- Pathology-informed decisions
- Connect tissue suitability, assay selection and interpretation.
- Coordinated sample use
- Plan tissue allocation and laboratory work together, with one point of contact.
IHC targets in our assay library
Explore selected targets from our IHC assay library. Search by marker, filter by research category, or select a target to discuss assay requirements with our team.
Matches any selected category. No selection shows all targets.
Each marker shows its research categories. Filter by category or search by marker name.
No matching targets
Try another marker or category, or reset your search to browse the library.
Ask about a targetAssay optimization, controls and scoring
We review the assay protocol, controls and scoring criteria against your study requirements before testing begins.
Antibody clone, dilution, antigen retrieval and detection conditions are optimized using appropriate control tissue on the selected staining platform.
Positive and negative FFPE control tissue is stained alongside study samples to assess assay performance and background staining.
Where additional validation is required, we agree the scope and acceptance criteria with you. Assessments may include specificity, sensitivity and reproducibility.
Our pathologists apply the scoring criteria agreed for your study, such as H-score or percentage of positive cells. PD-L1 scoring may use tumor proportion score (TPS) or combined positive score (CPS), as appropriate for the assay and indication.
IHC assay development for new targets
If your target is not in the library, we can assess it for assay development.
We begin by reviewing the target, tissue type and intended use of the assay. We then identify candidate antibodies and suitable positive and negative control material, including tissue from our repository where available.
Development includes antibody screening, titration, and optimization of antigen retrieval and detection on the selected automated platform. Normal tissue microarrays can be used to compare expression across nonmalignant tissues and assess staining patterns alongside tumor tissue.
We agree the scoring method and any further validation needed for your study. The final protocol and control requirements are documented before study testing.
HBS & DONOR DATA
Quality biospecimens & data for precision medicine
UK · Italy · FranceDonors from participating medical centers, with informed consent and ethics approval.
FFPE surgical samplesPrimary tumors, metastases and normal (non-malignant) tissue.
Breadth of donor profiles
Specimen, treatment, outcomes and molecular data, structured at the patient level.
Patient trajectory
- Primary tumors & matched distant metastases
- Matched normal tissue
- Neoadjuvant & adjuvant treatment
- Standard-of-care targeted therapies & checkpoint inhibitors
- Treatment regimen, line & dates
- Responders & non-responders
Structured outcomes
- Clinician-recorded response
- Overall survival (months)
- Progression-free survival (months)
- Time to events (months)
- Last follow-up
- Event flags: recurrence / death / composite
Molecular characterization
- IHC
- FISH
- RNA-ISH
- NGS: SNVs, CNVs & fusions
Treatment context
- Checkpoint inhibitors & IO
- Antibodies & ADCs
- Kinase inhibitors
- CDK4/6 inhibitors
- PI3K/mTOR inhibitors
- PARP inhibitors
Records are fully anonymized. Available fields vary by donor and reflect clinical practice at the source center. Cohorts are selected to meet your project’s requirements.
Explore early-stage, advanced and treatment-defined tissue cohorts with linked clinical and molecular data.
Explore tissue cohortsWork with our experienced scientific team to tailor biospecimens, data, and integrated services to your research needs.
Our approach begins with our customers’ science.
We focus our acquisition on patient cohorts that meet the needs of biopharma, clinical, and translational researchers.
Plan your study
Discuss your IHC study
Tell us your target, tissue type and study requirements. Our team will review assay availability, cohort requirements and any development or transfer work needed to prepare a quote.